Dare Bioscience
DARE
19 hedge funds and large institutions have $2.11M invested in Dare Bioscience in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.35% less ownership
Funds ownership: 21.77% → 16.42% (-5.3%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
30% less funds holding
Funds holding: 27 → 19 (-8)
97% less capital inflows, than outflows
Capital inflows: $22.6K | Capital outflows: $891K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
+$10.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.82K |
| 3 |
Bank of New York Mellon
New York
|
+$4.48K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$2.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu KCG Holdings
New York
|
-$306K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$252K |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
-$165K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$78K |
| 5 |
BlackRock
New York
|
-$25.5K |
DARE Hedge Fund Activity: Q2 2017 in Review
19 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q2 2017, worth a combined $2.11M — down 59% from $5.13M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of DARE and 0 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $10.9K. The largest seller was Virtu KCG Holdings, cutting an estimated $306K.
- 19 institutional investors held Dare Bioscience (DARE) as of Q2 2017, down from 27 in Q1 2017.
- Funds reported $2.11M of Dare Bioscience stock for Q2 2017, down 59% quarter-over-quarter.
- 0 funds opened new Dare Bioscience positions in Q2 2017 and 8 closed out, a net change of -8 holders.
- The largest Dare Bioscience buyer in Q2 2017 was Tower Research Capital (TRC), an estimated $10.9K added.
- The largest Dare Bioscience seller in Q2 2017 was Virtu KCG Holdings, an estimated $306K sold.
Based on aggregated 13F filings for Q2 2017.